| DC46463 |
Monophosphoryl lipid A
Featured
|
Monophosphoryl lipid A (Glucopyranosyl lipid A) is a toll-like receptor 4 agonist. Monophosphoryl lipid A is derived from the cell wall of nonpathogenic Salmonella. Monophosphoryl lipid A can be used for the research of immunization and vaccine. |
|
| DC46471 |
RP101988
Featured
|
RP101988, the major active metabolite of Ozanimod, is a selective, potent S1PR1 (sphingosine-1-phosphate receptor 1) agonist, with EC50s of 0.19 nM and 32.8 nM for S1PR1 and S1PR5, respectivlely. |
|
| DC46491 |
BAY-8400
Featured
|
BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor with IC50 of 81 nM. BAY-8400 shows synergistic activity of DNA-PK inhibition when combined with DNA damage inducing cancer therapy, like targeted alpha radiation. |
|
| DC46500 |
I-BET282E
Featured
|
I-BET282E is a pan-inhibitor of all eight BET bromodomains, and selectivity over other representative bromodomain-containing proteins. I-BET282E shows pIC50s ranging 6.4-7.7 for BRD2 (BD1/BD2), BRD2 (BD1/BD), BRD3 (BD1/BD), and BRD4 (BD1/BD). |
|
| DC46502 |
Brilacidin
Featured
|
Brilacidin (PMX 30063) is an anti-infective antimicrobial with MIC90s of 1 and 8 μg/mL for Gram-positive bacteria Streptococcus pneumonia and Streptococcus viridans, and MIC90 of 8 and 4 μg/mL for Gram-negative bacteria Haemophilus influenza and Pseudomonas aeruginosa. Brilacidin is a defensin mimetic antibiotic compound. |
|
| DC46524 |
HAIYPRH hydrochloride
Featured
|
HAIYPRH hydrochloride, a targeting ligand, can specially bind to transferrin receptor (TfR). HAIYPRH hydrochloride can mediate the transport of nanocarriers across the blood-brain barrier. |
.png)
|
| DC46527 |
σ1 Receptor antagonist-1
Featured
|
σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pKi=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells. |
|
| DC46532 |
MAGL-IN-4
Featured
|
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain. |
|
| DC46535 |
THK-5475(THK 5475)
Featured
|
THK-5475(THK5475) is a precursor of THK-5470, a monoamine oxidase-B(MAO-B) imaging probe, could be used for neurological diseases study (from patent EP2019-846498). |
|
| DC46604 |
CMD178
Featured
|
CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling. CMD178 also is an inhibitor of STAT5 and inhibit Treg cell development. |
|
| DC46625 |
HCV-IN-30
Featured
|
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC50s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively. |
|
| DC46639 |
WH-4-025
Featured
|
WH-4-025 is a Salt-inducible kinase (SIK) inhibitor (WO2016023014 A2). |
|
| DC46686 |
(R)-Pirtobrutinib
Featured
|
(R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. |
|
| DC46690 |
Gap 27
Featured
|
Gap 27 is a synthetic connexin-mimetic peptide and acts as a gap junction inhibitor. Gap 27 is highly effective in interrupting co-operative cell-cell interactions, such as the synchronous beating of embryonic cardiomyocytes. |
.png)
|
| DC46693 |
DAMGO
Featured
|
DAMGO (DAGO) is a potent and selective μ opioid receptor agonist with ki of 17 nM. |
|
| DC46694 |
OT-82
Featured
|
OT-82 is a novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with average IC50s of 13.03 nM in non-HP cancer cells and 2.89 nM in HP cancer cells, respectively. |
|
| DC57060 |
Glucocorticoid receptor modulator-1
Featured
|
A novel Glucocorticoid receptor modulator. |
|
| DC57061 |
EHP-101 (VCE- 004.8)
Featured
|
EHP-101 (VCE-004.8) is an orally active, specific PPARγ and CB2 receptor dual agonist. EHP-101 inhibits prolyl-hydroxylases (PHDs) and activates the HIF pathway. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. EHP-101 (20 mg/kg/day; i.p.; for 3 weeks) induces a significant reduction in body weight gain, total fat mass, adipocyte volume and plasma triglycerides levels in HFD mice. |
|
| DC57070 |
PY-60
Featured
|
PY-60 is a novel activator of YAP-dependent gene expression.It targets ANXA2 in the Hippo pathway.
PY-60 targets ANXA2 to activate YAP[1].
PY-60, a thiazole-substituted derivative, dose-dependently induces luciferase activity in 293A-TEAD-LUC cells in the presence or absence of serum when cells were plated at high cell density (EC50= 1.5 and 1.6 µM, respectively). PY-60 treatment also dose-dependently promoted the association of YAP and TEAD proteins in cells and induced the nuclear localization of YAP in response to increased cell density. PY-60 robustly increases the levels of YAP-controlled transcripts (that is, ANRKD1, CYR61 and CTGF) in 293A cells and other human cell lines (that is, MCF10A, HEK293T, H69 and HaCaT), but did not augment the levels of YAP itself (YAP1)[1].
PY-60 activates a proproliferative, YAP-dependent transcriptional program in the adult animal capable of remodeling the epidermis through proliferation[1].
PY-60 liberates the ANXA2-YAP complex from the cell membrane and competes for ANXA2 binding of phosphoinositides[1].
PY-60 (10 uM; applied topically to the dorsal skin of wild-type adult C57BL/6 mice over the course of 10 days) promotes a dramatic expansion of keratinocytes and K14-positive precursors, as assessed by hematoxylin and eosin and anti-K14 histological staining at the study end. PY-60 results in an approximate doubling of epidermal thickness, a result derived from an increased number of keratinocytes per unit length of skin[1].
|
|
| DC57071 |
HB007
Featured
|
HB007 is a novel small-molecule degraders of the small ubiquitin-related modifier 1 (SUMO1). |
|
| DC60115 |
Enfuvirtide Acetate
Featured
|
Enfuvirtide acetate salt is a linear synthetic peptide made of 36 amino acids. It has an acetylated N-terminus and a carboxamide C-terminus. |
|
| DC57073 |
VX-150
Featured
|
VX-150 (EOS-62073), a NaV1.8 blocker, is currently in a phase II clinical trial for the treatment of patients with acute pain. VX-150 significantly alleviates postoperative pain. |
|
| DC60116 |
Pimethixene
Featured
|
Pimethixene or Calmixen is antihistamine and anticholinergic of the thioxanthene chemical class that is often used to treat hyperactivity, anxiety, sleep disorders, and allergy. |
|
| DC60117 |
RS-25344 hydrochloride
Featured
|
RS-25344 HCl is a potent and selective phosphodiesterase (PDE) 4 inhibitor (IC50 values are 0.28, > 100, 160 and 330 nM at PDE4, PDE1, PDE2 and PDE3 respectively). It inhibits eosinophil chemotaxis and increases progressive motility of spermatozoa in vitro. |
|
| DC57076 |
GPR65 agonist (BTB09089)
Featured
|
GPR65 agonist (BTB09089) is a novel GPR65 agonist.
|
|
| DC60118 |
Fezolinetant HCl
Featured
|
Fezolinetant, also known as ESN-364, is Neurokinin-3 (NK-3) receptor antagonist which has been optimized for use in women’s health, and is being developed for sex-hormone related disorders such as endometriosis, polycystic ovarian syndrome and uterine fibroids. |
|
| DC57080 |
XEN723
Featured
|
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively. |
|
| DC57081 |
FIDAS-3
Featured
|
FIDAS-3 is a stilbene derivative and is a potent Wnt inhibitor with an IC50 of 4.9 μM for methionine S-adenosyltransferase 2A (MAT2A). FIDAS-3 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding. FIDAS-3 has anticancer activities. |
|
| DC57083 |
Necrostatin-34
Featured
|
Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain. |
|
| DC57085 |
TAK-653
Featured
|
TAK 653 (also known as NBI 1065845) is an oral small molecule, positive allosteric modulators of AMPA (AMPA-PAM) receptors |
|
